Trastuzumab: A picky partner?

Clinical Cancer Research

Volumn 15, Issue 20, 2009, Pages 6311-6313

  McArthur, Heather L ^a   Hudis, Clifford A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEMOPOIETIC GROWTH FACTOR; LAPATINIB; PACLITAXEL; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CELL DIFFERENTIATION; CELL GROWTH; CELL SURVIVAL; CYTOTOXICITY; DRUG MECHANISM; DRUG TARGETING; HUMAN; METASTASIS; NONHUMAN; NOTE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RELAPSE; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 70350223973     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1917     Document Type: Note

References (12)

1. Francia G, Man S, Lee C-J, et al. Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts. Clin Cancer Res 2009;15:6358-6366
2. Hudis CA. Trastuzumab-mechanismof action and use in clinical practice. N Engl J Med 2007;357: 39-51. (Pubitemid 47026733)
3. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182
4. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpressesHER2. N Engl J Med 2001;344:783-792
5. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684 (Pubitemid 41464706)
6. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672 (Pubitemid 41464705)
7. von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03-05 study. J Clin Oncol 2009;27:1999-2006.
8. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355: 2733-2743 (Pubitemid 46021510)
9. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-436
10. Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008;358:1663-1671 (Pubitemid 351549913)
11. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008;26:1642-1649
12. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-820 (Pubitemid 43290919)